683 Capital Management Has Raised By $1.05 Million Its Fate Therapeutics (FATE) Position; Ls Investment Advisors Increased Its Ametek (AME) Stake

April 17, 2018 - By Maria Brooks

AMETEK, Inc. (NYSE:AME) Logo

Ls Investment Advisors Llc increased Ametek Inc (AME) stake by 83.56% reported in 2017Q4 SEC filing. Ls Investment Advisors Llc acquired 11,393 shares as Ametek Inc (AME)’s stock rose 3.40%. The Ls Investment Advisors Llc holds 25,028 shares with $1.81M value, up from 13,635 last quarter. Ametek Inc now has $17.71B valuation. The stock increased 1.19% or $0.9 during the last trading session, reaching $76.5. About 713,110 shares traded. AMETEK, Inc. (NYSE:AME) has risen 40.32% since April 17, 2017 and is uptrending. It has outperformed by 28.77% the S&P500.

683 Capital Management Llc increased Fate Therapeutics Inc (FATE) stake by 25.78% reported in 2017Q4 SEC filing. 683 Capital Management Llc acquired 175,000 shares as Fate Therapeutics Inc (FATE)’s stock rose 82.53%. The 683 Capital Management Llc holds 853,800 shares with $5.22 million value, up from 678,800 last quarter. Fate Therapeutics Inc now has $608.46 million valuation. The stock increased 3.41% or $0.38 during the last trading session, reaching $11.53. About 240,480 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 112.01% since April 17, 2017 and is uptrending. It has outperformed by 100.46% the S&P500.

Among 10 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Fate Therapeutics had 21 analyst reports since October 6, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Buy” rating and $7.0 target in Wednesday, November 1 report. The firm earned “Outperform” rating on Tuesday, March 6 by BMO Capital Markets. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Buy” rating by Leerink Swann on Friday, September 8. The firm has “Buy” rating given on Tuesday, March 6 by Piper Jaffray. The rating was reinitiated by H.C. Wainwright with “Buy” on Thursday, October 12. On Friday, April 6 the stock rating was maintained by Wells Fargo with “Buy”. On Wednesday, December 13 the stock rating was maintained by H.C. Wainwright with “Buy”. Wedbush maintained the shares of FATE in report on Tuesday, March 6 with “Outperform” rating. H.C. Wainwright maintained the stock with “Hold” rating in Thursday, March 29 report. As per Thursday, September 22, the company rating was initiated by TH Capital.

Investors sentiment decreased to 1.58 in 2017 Q4. Its down 0.21, from 1.79 in 2017Q3. It is negative, as 9 investors sold FATE shares while 17 reduced holdings. 17 funds opened positions while 24 raised stakes. 32.27 million shares or 31.43% more from 24.55 million shares in 2017Q3 were reported. 683 Capital Management Llc reported 0.44% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). 6,013 are owned by State Bank Of America De. First Manhattan owns 250 shares or 0% of their US portfolio. Vigilant Mgmt Ltd holds 1,000 shares. 96,262 were accumulated by Tiaa Cref Inv Limited Co. Tci Wealth Advisors invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). 534,969 were reported by State Street Corporation. Bank & Trust Of Montreal Can reported 3,000 shares. Deutsche Commercial Bank Ag stated it has 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). 2,000 are held by Atlantic. 6,228 were accumulated by Barclays Pcl. New York-based Blackrock has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Parallax Volatility Advisers Limited Partnership holds 0% or 5,796 shares in its portfolio. Doheny Asset Mgmt Ca has 14,000 shares. Neuberger Berman Gp has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE).

683 Capital Management Llc decreased Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) stake by 39,500 shares to 200,000 valued at $25.41 million in 2017Q4. It also reduced Tripadvisor Inc (NASDAQ:TRIP) stake by 41,000 shares and now owns 259,000 shares. Inspired Entmt Inc was reduced too.

Ls Investment Advisors Llc decreased Cvs Health Corp (NYSE:CVS) stake by 11,109 shares to 190,562 valued at $13.82 million in 2017Q4. It also reduced Estee Lauder Cos Cl A (NYSE:EL) stake by 9,567 shares and now owns 8,011 shares. Stanley Black & Decker Inc (NYSE:SWK) was reduced too.

Among 14 analysts covering AMETEK (NYSE:AME), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AMETEK had 63 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained AMETEK, Inc. (NYSE:AME) rating on Wednesday, August 5. Oppenheimer has “Buy” rating and $59 target. The rating was maintained by Wells Fargo on Thursday, January 18 with “Buy”. BMO Capital Markets maintained it with “Buy” rating and $6700 target in Tuesday, June 27 report. The stock of AMETEK, Inc. (NYSE:AME) earned “Outperform” rating by RBC Capital Markets on Friday, August 5. RBC Capital Markets maintained AMETEK, Inc. (NYSE:AME) on Wednesday, October 11 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Wednesday, October 28 with “Buy”. RBC Capital Markets maintained AMETEK, Inc. (NYSE:AME) rating on Wednesday, October 28. RBC Capital Markets has “Outperform” rating and $62 target. The rating was downgraded by Atlantic Securities on Friday, April 29 to “Neutral”. Stifel Nicolaus maintained it with “Buy” rating and $92.0 target in Thursday, February 1 report. Bank of America upgraded the stock to “Buy” rating in Thursday, October 29 report.

Since December 11, 2017, it had 0 buys, and 13 insider sales for $9.09 million activity. 25,965 AMETEK, Inc. (NYSE:AME) shares with value of $1.86 million were sold by ZAPICO DAVID A. On Friday, March 9 the insider Conti Anthony James sold $316,476. Shares for $391,550 were sold by Kohlhagen Steven W on Friday, March 9. $1.26 million worth of AMETEK, Inc. (NYSE:AME) shares were sold by EGINTON WILLIAM D. VARET ELIZEBETH R also sold $233,700 worth of AMETEK, Inc. (NYSE:AME) shares. WILLIAMS DENNIS K sold 4,050 shares worth $309,672. The insider Oscher Ronald J sold 14,976 shares worth $1.13M.

AMETEK, Inc. (NYSE:AME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: